- Novo Nordisk has revised its 2025 full-year sales growth forecast to 8% to 14% at constant exchange rates, down from a previous estimate of 13% to 21%.
- The operating profit growth forecast has also been adjusted, now expected to be 10% to 16% at constant exchange rates, down from 16% to 24% previously forecasted.
- The adjustment in the sales outlook has been attributed to a lower growth forecast for the second half of the year.
- The penetration of Wegovy in the cash channel has been lower than expected, impacting sales predictions.
- Novo Nordisk anticipates financial items net to produce a gain of approximately DKK 3 billion for 2025.
- In reaction to the updated forecasts, Novo Nordisk shares fell by 7.3%, closing at DKK 418.15 with a trading volume of 1.64 million shares.
- Analyst ratings show 21 buys, 8 holds, and 4 sells for Novo Nordisk.
“`
A look at Novo Nordisk A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysing the Smartkarma Smart Scores for Novo Nordisk A/S, the company shows a promising long-term outlook. With solid scores in Dividend, Growth, Resilience, and Momentum, Novo Nordisk is positioned well for future success. The company’s strong focus on diabetes care, along with its diverse product offerings in areas such as haemostatis management and hormone replacement therapy, contributes to its positive growth outlook.
Novo Nordisk’s emphasis on maintaining a stable dividend, coupled with its ability to adapt and innovate in the pharmaceutical industry, showcases its resilience. Furthermore, the company’s consistent momentum signifies good potential for future market performance. Overall, Novo Nordisk A/S appears to be a strong player in the pharmaceutical sector with a promising outlook for investors seeking a stable and growth-oriented investment option.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
